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Abstract Type 1 diabetes is an autoimmune disease arising
from the destruction of pancreatic insulin-producing beta cells.
The disease represents a continuum, progressing sequentially at
variable rates through identifiable stages prior to the onset of
symptoms, through diagnosis and into the critical periods that
follow, culminating in a variable depth of beta cell depletion.
The ability to identify the very earliest of these presymptomatic
stages has provided a setting in which prevention strategies can
be trialled, as well as furnishing an unprecedented opportunity to
study disease evolution, including intrinsic and extrinsic initia-
tors and drivers. This niche opportunity is occupied by Type 1
Diabetes TrialNet, an international consortium of clinical trial
centres that leads the field in intervention and prevention studies,
accompanied by deep longitudinal bio-sampling. In this review,
we focus on discoveries arising from this unique bioresource,
comprisingmore than 70,000 samples, and outline the processes
and science that have led to new biomarkers and mechanistic
insights, as well as identifying new challenges and opportunities.
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We conclude that via integration of clinical trials and mechanis-
tic studies, drawing in clinicians and scientists and developing
partnership with industry, TrialNet embodies an enviable and
unique working model for understanding a disease that to date
has no cure and for designing new therapeutic approaches.
Keywords Autoimmunity .Mechanistic studies . Review .
Type 1 diabetes
Abbreviations
CM Central memory
nPOD Network for Pancreatic Donor
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Introduction
Type 1 diabetes, a complex, three-stage, chronic autoimmune
disease, accounts for 5–10% of all cases of diabetes. It is
estimated that, worldwide, ~78,000 individuals under age
20 years are diagnosed with the disease annually, as well as
a comparable number of adults. This disease rate has doubled
every two decades since the middle of the last century and
shows little sign of abating [1]. In 1974, this form of diabetes
was first linked to an autoimmune process by the detection of
circulating islet cell-specific autoantibodies [2]. Since then,
global research efforts have transformed our understanding
of the disease through classical studies of epidemiology, pa-
thology, genetics and natural history. As a result, we now
know that type 1 diabetes is an autoimmune disease arising
from the destruction of pancreatic insulin-producing beta cells
[3]. But behind that simple statement lie many complexities.
Although strong links to HLA class I and II genes indicate a
role for T lymphocytes in the disease process, numerous other
cellular and molecular immune pathways have been
implicated and disease initiators and drivers remain to be iden-
tified with certainty.
The 1974 discovery did not just achieve the subdivision of
a syndrome—it is also of great practical importance.
Autoantibodies directed against specific targets in the beta cell
show high sensitivity and specificity for the identification of
individuals at risk of future development of type 1 diabetes, in
the absence of blood glucose abnormalities [4]. The possibil-
ity of studying a disease prodrome sets type 1 diabetes apart
from almost all other immune-mediated inflammatory dis-
eases and has additional ramifications. Recently, for example,
it has spurred proposals for a new type 1 diabetes nosology, in
which stage 1 disease is defined as the simple presence of
autoantibodies; in stage 2 this is accompanied by abnormal
blood glucose control and stage 3 is frank diabetes [5] (Fig.
1a). But perhaps of greatest importance, the ability to identify
at-risk individuals in stages 1 and 2 has provided a setting in
which type 1 diabetes prevention can be contemplated, as well
as an unprecedented opportunity to study the evolution of the
disease.
Against this backdrop, Type 1 Diabetes TrialNet was
formed in 2003, funded by the National Institute of Diabetes
and Digestive and Kidney Disease (NIDDK) of the National
Institutes of Health and the JDRF, with the objective of
developing a clinical network approach to type 1 diabetes
prevention, while at the same time promoting studies of dis-
ease pathogenesis [6]. In this review, we will focus on the
latter function.
Type 1 Diabetes TrialNet
Type 1 Diabetes TrialNet (TrialNet) has developed into an
international network of researchers who are exploring ways
to prevent, delay and reverse the progression of type 1 diabe-
tes. TrialNet was established in response to the Surgeon
General’s Report ‘Healthy People 2000’. This report identi-
fied diabetes as a US national health objective and in response
the US Congress created the Diabetes Research Working
Group (DRWG). One of this group’s earliest recommenda-
tions was the setting up of a programme of research studies
and clinical trials to prevent type 1 diabetes [6].
Since 2016, TrialNet has conducted clinical trials with re-
searchers from 18 clinical centres in the USA, Canada,
Finland, UK, Italy, Germany, Sweden, Australia and New
Zealand. In addition, more than 150 medical centres and phy-
sician offices are participating in the network, offering major
research opportunities (www.trialnet.org/our-research). One
of the lynchpin programmes is the Pathway to Prevention
study (protocol TN01), through which relatives of
individuals with type 1 diabetes are screened for the
presence of circulating autoantibodies. Those identified as
being at increased risk (individuals in stage 1 or 2 of the
disease) are followed up and offered clinical trial
opportunities. During follow-up, individuals attend regular
assessment visits that include the collection of blood for
continued evaluation of islet cell autoantibody status and the
collection of longitudinal samples for mechanistic studies, as
well as determination of metabolic status (dysglycaemia,
frank diabetes) and systematic collection of metadata
(Table 1). In addition to TN01, TrialNet has conducted pivotal
clinical trials with the following aims: (1) to determine wheth-
er new treatments can delay or prevent the onset of clinically
overt type 1 diabetes in individuals at prediabetic stages and
(2) to preserve insulin production in individuals newly diag-
nosed with clinical type 1 diabetes (Fig. 1b). The collection of
an array of longitudinal bio-samples from these studies (both
concluded and ongoing) provides the added value of potential
for understanding mechanisms of disease and therapeutic
effects, as well as identifying appropriate biomarkers.
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It is worth noting that TN01 is not a ‘traditional’
natural history study but rather a ‘feeder’ study designed
to identify individuals at various disease stages for appro-
priate prevention trials and to help to understand disease
progression. As a result, there is scant information on the
age of seroconversion of TrialNet participants, or on the
types of autoantibodies with which they first present. This
is a potentially important limitation, since data have
emerged to indicate that different disease phenotypes
may exist (e.g. HLA-DR4/DQ8 haplotype is linked to in-
sulin autoantibodies at seroconversion, while HLA-DR3/
DQ2 haplotype is linked to anti-GAD at seroconversion
Genetic risk Immune 
activation
Stage 1 Stage 2 Stage 3 Post-
diagnosis
Normal 
blood sugar
Clinical
diagnosis
Abnormal 
blood sugar
≥2 autoantibodies ≥2 autoantibodies ≥2 autoantibodies
a  Path to type 1 diabetes
b  Type of TrialNet study
PTP (TN01)
MMF-Daclizumab (TN02)
Nutritional intervention (TN06)
Oral insulin (TN07)
MMTT-GST (TN03)
T-cell validation assay  (TN04)
Rituximab (TN05)
GAD alum (TN08)
Teplizumab (TN10)
Abatacept (TN18)
Immune effects of
oral insulin (TN20)
Canakinumab (TN14)
LIFT (TN16)
ATG-G-CSF (TN19)
Abatacept (TN09)
= Observational                                       = Intervention
= Improving metabolic or immunological assessments                                 = Mechanistic
Fig. 1 Type 1 diabetes: a disease with three stages of pathology and
various opportunities for intervention with disease-modifying therapies
and mechanistic analysis. (a) Stage 1 is the start of the disease—there are
no symptoms and blood sugar remains normal but the autoimmune pro-
cess has already begun, manifested by multiple autoantibodies against
beta cell targets. In stage 2, like stage 1, autoimmunity is the key feature
and there are no symptoms; however, blood sugar control has now be-
come abnormal due to loss of beta cells. From stages 1 and 2, there is an
extremely high risk of progression to stage 3, when symptoms of diabetes
emerge (thirst, weight loss and fatigue) due to significant beta cell loss,
and the clinical diagnosis is made. (b) Each stage of the disease is
encompassed within TrialNet and offers an opportunity for interventions
or mechanistic analysis. Examples of TrialNet studies (concluded and
ongoing) are listed in association with the targeted disease stage. ATG-
G-CSF, anti-thymocyte globulin+granulocyte colony stimulating factor;
GST, glucagon stimulation test; LIFT, long-term investigative follow-up;
MMF, mycophenolate mofetil; MMTT, mixed meal tolerance test; PTP,
Pathway to Prevention study. Abatacept is a CTLA-4–immunoglobulin;
canakinumab is an anti-IL1β monoclonal antibody (mAb); rituximab is
an anti-CD20 mAb; teplizumab is an anti-CD3 mAb
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[7]). These phenotypes may reflect different endotypes
(i.e. different aetiopathogenesis) and/or may be suited to
different prevention strategies and TrialNet can begin to
address these issues in future clinical trials, either through
using HLA genotype as a surrogate, or through modifica-
tion of participant screening strategies.
TrialNet ancillary studies
Since inception, TrialNet has thus assembled an enviable
bioresource of longitudinal samples and metadata, which
is open to access by the global research community
through an ancillary studies programme. The collection
contains over 70,000 samples gathered from over 7500
donors at various follow-up time points and includes ge-
nomic DNA, whole-blood RNA, serum, plasma and pe-
ripheral blood mononuclear cells. Further, specialised
sampling and additional metadata can also be acquired
in real-time studies. This is the ‘living biobank’ approach,
which provides investigators with the opportunity to ob-
tain on-demand biological samples from selected
individuals who are engaged in TrialNet protocols.
Studying these samples offers opportunities for natural
history studies and can provide critical understanding as
to how or why specific intervention strategies did or did
not deliver a specified primary study outcome.
As of 31 December 2016, more than 25,500 archived sam-
ples have been distributed to 35 laboratories for 48 ancillary
studies (Fig. 2).
Thus far, questions addressed in TrialNet ancillary
studies have focused on the immune system (mainly
studies on T cells) but there are also studies on beta cells
as well as studies utilising multi-dimensional platform
technologies (‘omics’) (Fig. 3a). Serum and plasma repre-
sent the most-requested types of samples across all types
of studies (Fig. 3b).
TrialNet ancillary studies signpost key
breakthroughs
The TrialNet programme of ancillary studies has provided
more than 40 investigators with more than 25,500 samples
and as such there is a wealth of information fromwork already
done addressing important questions. Of relevance is the pres-
ence of more than 2900 donors who were analysed by differ-
ent TrialNet investigators to address various scientific ques-
tions (Fig. 4). This provides a great opportunity to integrate
data from different studies performed in various laboratories
on the same individuals. To best enhance this asset, TrialNet is
currently seeking new collaborations that aim to analyse and
integrate data obtained from existing ancillary studies. This
will provide added value to TrialNet, its collaborators and
the type 1 diabetes research community. In addition to this
work in progress, several ancillary studies have been complet-
ed to date and have provided transformational insights, chang-
ing the way in which we view the disease. A selection of these
and their key breakthroughs are described briefly below.
Definition of type 1 diabetes endotypes From a clinical
standpoint, it is obvious that type 1 diabetes is a heterogeneous
disease. For example, it can manifest very aggressively in a 3-
year-old child who has rapid symptomatic onset, type-1-
diabetes-associated autoantibodies, exceedingly low C-
peptide levels, disease-predisposing HLA genes and an asso-
ciated inflammatory process such as coeliac disease. But type
1 diabetes can also occur in a 40-year-old individual with
limited HLA risk, detectable C-peptide, a mild, indolent onset
and no other autoimmune diseases. With insulin replacement
by injection being the only approved therapy for type 1 dia-
betes, there has seemed little need to identify disease hetero-
geneity from a clinical–pathological perspective [8].
However, this heterogeneity is emerging as a potentially im-
portant concept. Data from the T1D Exchange Clinic
Network, for instance, demonstrated heterogeneity in loss of
Table 1 Pathway to Prevention
study (TN01) Serological status Screened
a Enrolled in monitoringb
All individuals 178,648 5506
Autoantibody negativec 170,487 155
Positive for one autoantibodyc 3273 2144
Positive for two or more autoantibodiesc 4888 3207
Data as of 31 December 2016; a total of 835 individuals progressed to type 1 diabetes
a Eligible individuals who were genetically at risk and who were tested for autoantibodies through TrialNet
b Individuals who were eligible for and enrolled in active monitoring through TrialNet for metabolic and clinical
markers on an annual or semi-annual basis
c Autoantibody-negative individuals underwent annual monitoring andmultiple autoantibody-positive individuals
underwent semi-annual monitoring. Most individuals confirmed positive for a single autoantibody underwent
annual monitoring, although some converted to semi-annual monitoring
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insulin secretion at each stage of disease [9]. Other studies,
especially those of pancreas samples post-mortem in the
Network for Pancreatic Donor (nPOD) collection, revealed
considerable variability in the degree of residual insulin-
reactive staining in recent-onset disease [10]. This prompted
a more focused set of questions around whether endotypes
exist within type 1 diabetes, which could have dramatic im-
pact on our understanding of disease processes and therapeu-
tic approaches. An endotype is a disease subtype defined by a
distinct functional or pathobiological mechanism [11]. Results
generated in a TrialNet ancillary study took the first steps
towards the description of type 1 diabetes endotypes, using
two complementary analyses of tissue and blood to identify
disease-related subphenotypes in individuals with type 1 dia-
betes. The blood-based study (including samples from TN01)
showed that approximately one-half of the individuals,
analysed close to diagnosis, had autoreactive T cell responses
characterised by the proinflammatory cytokine IFN-γ, where-
as one-half were distinguished as having IL-10 responses (typ-
ical of immune regulation) along with significantly fewer au-
toantibodies. In the tissue-based study, analysis of pancreases
obtained close to disease diagnosis (through the nPOD net-
work) showed that approximately one-half of the individuals
had an inflammatory islet infiltration distinguished by high
numbers of CD20+ B lymphocytes, whereas one-half had
sparse infiltration and significantly fewer B lymphocytes
[12]. Thus, this work shows the existence of blood and tissue
phenotypes (inflammatory CD20High vs regulatory CD20Low)
that are likely to be related to each other and to variable rates
of disease progression. Despite the fact that formal proof of
such a link is still lacking–since blood and pancreas samples
were collected from distinct individuals–this study provides
the first example of a pathophysiological basis for disease
heterogeneity that may have direct relevance to stratification
for therapeutic trials [12].
Discovery of circulating markers of beta cell killing and/or
stress Another important gap in type 1 diabetes research re-
mains the lack of biomarkers that reflect an authentic signature
of beta cell death and/or stress. Resolving this issue may also
improve our ability to optimally time immunomodulatory
treatments and other forms of interventions in type 1 diabetes.
Several investigators have recently developed methods for
assessing beta cell death in vivo by measuring the relative
amount of beta cell-derived insulin encoding DNA (INS
DNA) in the circulation. This analysis involves quantitative
PCR amplification of INS DNA, with epigenetic marks that
identify the DNA source as cells that actively transcribe insu-
lin. Since the only significant source of non-methylated INS
DNA in the body is the beta cell, the level of unmethylated
INS DNA in the circulation reflects the active rate of beta cell
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death [13]. A recent TrialNet ancillary study determined levels
of beta cell killing using this approach in individuals at risk of
type 1 diabetes (from TN01). This study demonstrated that
beta cell death can be found before the onset of type 1 diabe-
tes. Importantly, the study gave insight into the tempo of the
disease: while episodes of beta cell killing associated with a
decline in insulin secretion were detected in the prediabetes
period, there was a dramatic increase in killing in the peri-
diagnosis period [14]. Although the ‘unmethylated INS
DNA’ assay has yet to be fully validated [15], these data sup-
port the notion that a blood test that measures beta cell death in
the setting of type-1-diabetes-associated autoimmunity can
potentially be used in the future as the first surrogate marker
of its kind, able to monitor beta cell ‘health-status’ during
prevention and intervention studies.
Beta cells, like all professional secretory cells, naturally
undergo high levels of endoplasmic reticulum stress as a result
of their normal secretory physiology [16]. A hallmark of beta
cell endoplasmic reticulum dysfunction is the accumulation
and secretion of inadequately processed proinsulin molecules
[17]. Therefore, using the proinsulin/C-peptide ratio (PI/C) as
a non-invasivemarker of beta cell dysfunction could provide a
means to identify individuals at risk of developing type 1
diabetes prior to the onset of massive beta cell destruction.
Sims et al recently reported that in archived samples from
autoantibody-positive individuals enrolled in the Pathway to
Prevention study (TN01), fasting PI/C was significantly in-
creased ∼12 months prior to onset of type 1 diabetes [18].
Elevations were most pronounced in children aged ≤10 years,
whose median PI/C was threefold higher than that of individ-
uals who did not progress to type 1 diabetes. However, even
among the entire group, increased PI/C was associated with
increased odds of progression to type 1 diabetes after correc-
tion for age and BMI [18]. PI/C remains likely to be an infor-
mative and useful component of type 1 diabetes risk predic-
tion algorithms, as well as an important biomarker of beta cell
dysfunction in treatment trials. In addition, these results were
confirmed by recent data demonstrating that in situ (in pan-
creas sections from diabetes autoantibody-positive donors),
insulin area and beta cell mass can be maintained prior to
disease onset and that production of proinsulin increases
[19]. Using high-resolution confocal microscopy, this study
revealed a high accumulation of vesicles containing proinsulin
in beta cells from autoantibody-positive donors. This suggests
either a defect in proinsulin conversion or an accumulation of
immature vesicles due to an increase in insulin demand and/or
to a dysfunction in vesicular trafficking. Taken together, these
data suggest that prevention during stage 1 of the disease,
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when beta cell mass is still intact, could be a successful ther-
apeutic strategy.
Discovery of circulatingmicroRNAs associated with disease
progression It is now clear that rates of progression to clinical
symptoms vary significantly among individuals [5]. Thus, it
would be desirable to identify additional biomarkers that
could improve prediction beyond that afforded by autoanti-
body positivity. A recent study provided initial evidence that
levels of selected circulating microRNAs are associated with
increased risk of disease progression [20]. Augmented levels
of these microRNAs conferred increased risk in young
autoantibody-positive individuals enrolled in the Pathway to
Prevention study (TN01). Moreover, the levels of several of
the microRNAs associatedwith disease progression correlated
with multiple OGTT indices of beta cell function, including
both glucose and C-peptide area under the curve, peak C-
peptide, and composite metabolic scores. Of note, several of
these microRNAs have known influence on beta cell function
and insulin secretion. Additional studies are needed to validate
and expand these findings, which can be correlated with im-
munological and beta cell stress/death markers.
Discovery of an immunological biomarker of C-peptide
level decline TrialNet performed a clinical trial of immuno-
logical co-stimulation blockade using CTLA-4–immunoglob-
ulin (abatacept) in individuals newly diagnosed with type 1
diabetes (TN09). Two years of continuous treatment was as-
sociated with a slower decline of beta cell function and the
beneficial effect was sustained for at least 1 year after therapy
cessation [21]. To better understand the mechanism of this
therapeutic effect, Orban and colleagues conducted an ancil-
lary study to analyse immune cell subsets in treated and con-
trol individuals, using polychromatic flow cytometry [22].
The study revealed that continuous co-stimulation blockade
is associated with an inversion of conventional naive/memory
CD4+ Tcell subset status, marked by a significant reduction in
circulating CD4+CD45R0+CD62L+ central memory (CM) T
cells and concomitant increase in CD4+CD45R0−CD62L+ na-
ive T cells. These changes reverted after treatment cessation,
supporting a direct drug effect. Importantly, the study also
revealed that in placebo-treated individuals there was an in-
crease in the number of circulating CM CD4+ T cells and a
decrease in CD4-naive/CM T cell ratio, significantly associat-
ed with a subsequent rise in the rate of C-peptide decline.
Abatacept treatment significantly altered this association.
Mechanistically, this implies that the effect of co-stimulation
blockade on naive/CM status of CD4+ T cells is linked to its
therapeutic effect [22]. These data are the first to reveal an
immunological biomarker of C-peptide level decline in indi-
viduals in whom type 1 diabetes has recently developed. This
marker could assist in the prediction of progression of immu-
nological damage to beta cells at various stages of the disease
and provides a strong rationale for early therapeutic interfer-
ence in co-stimulation and generation/maintenance of im-
mune memory in type 1 diabetes. Currently, a TrialNet study
of abatacept is being conducted in those at stage 2 of disease
(i.e. with two autoantibodies and normal glucose tolerance)
(www.trialnet.org/our-research/prevention-studies) (TN18,
Fig. 1b).
Novel insights into disease pathogenesis Type 1 diabetes is
typically described as an immune-mediated disease in which
T cells drive the specific destruction of pancreatic insulin-
producing beta cells. Recent data arising from TrialNet ancil-
lary studies indicate that this T cell-centric view may need
broadening. The role of B lymphocytes in type 1 diabetes is
poorly understood despite autoantibodies being known robust
predictive biomarkers. From results of studies making use of
TrialNet samples, it is now becoming apparent that a breach in
B lymphocyte tolerance is also a major contributor to type 1
diabetes. The trigger for these findings is the success of TN05,
a clinical trial in individuals with new-onset type 1 diabetes,
using monoclonal anti-CD20 antibody therapy (rituximab) to
deplete CD20+ B cells. Those receiving active treatment
showed reduced decline in C-peptide secretion in the year
following introduction of therapy and better glycaemic control
with reduced requirements for exogenous insulin [23].
Disappointingly, however, clinical efficacy was not sustained
much beyond 1 year, prompting initiation of several TrialNet
ancillary studies designed to better understand this phenome-
non [24]. Meffre and co-workers, who previously reported
defective central and peripheral B cell tolerance checkpoints
resulting in the accumulation of self-reactive mature B cells in
individuals with type 1 diabetes [25], investigated whether
anti-B cell therapy modifies the frequency of autoreactive B
cells. They found that B cell depletion did not change the
frequencies of autoreactive and polyreactive B cells, which
remained elevated in all individuals after rituximab treatment.
There was a limited proliferative history of autoreactive B
cells after treatment but these clones were newly generated
B cells and not self-reactive B cells that had escaped depletion
and repopulated the periphery through homeostatic expan-
sion. Thus, anti-B cell therapy may provide a temporary re-
duction in autoimmune processes through B cell depletion.
However, repletion with autoreactive B cells after this therapy
may explain the relapse that occurs in many autoimmune in-
dividuals. This study adds weight to the emerging concept that
autoreactive B cells have a major pathogenic role in human
type 1 diabetes. Moreover, these and other studies support the
idea of trialling sequential therapy: first depleting B cells and
then addressing resurging T cell activation.
In accordance with this view, Cambier and colleagues dem-
onstrated that high-affinity insulin-binding B cells are present
in healthy individuals exclusively in the anergic naive com-
partment, while these insulin-binding B cells lose their anergic
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phenotype in individuals who are at risk of diabetes (TN01
participants) or who have new-onset (< 1 year) type 1 diabetes
[26]. These findings suggest that disruption of B cell anergy
may predispose individuals towards autoimmunity, consistent
with a potential early role for B cells in the development of
type 1 diabetes.
A further, often neglected, component of the immune re-
sponses in individuals with type 1 diabetes has been that of
innate immune pathways. A careful examination of the pe-
ripheral blood of relatives of individuals with type 1 diabetes
(TN01) and of individuals with established disease has re-
vealed a reduced number of circulating neutrophils. Indeed,
the higher the risk of progression to diabetes, the more pro-
nounced the reduction. This observation was possible through
direct access to fresh blood from donors participating in TN01
using the Living Biobank approach. The observed reduction
in circulating neutrophils is accompanied by the novel finding
that neutrophils infiltrate the pancreas of individuals with type
1 diabetes, studied as cadaveric organ donors, suggesting that
a disturbance in peripheral neutrophil regulation arises in par-
allel with neutrophil pancreas marginalisation [27]. Reduced
circulating neutrophils have also been found in individuals
with type 1 diabetes (<100 days from diagnosis) enrolled in
five different TrialNet intervention trials (TN02, TN05, TN08,
TN09 and TN14; Fig. 1b) [28]. It remains to be defined
whether this reduction may reflect the aetiopathology of dis-
ease or serve as a clinical biomarker of a subgroup of individ-
uals who develop diabetes.
Additional evidence pointing to the presence of innate im-
munemechanisms during the early stage of the disease (stage 1)
comes from Hessner’s group [29]. They used plasma-induced
transcriptional changes to investigate immune states within type
1 diabetes families (TN01 donors) and how these alter over
time with either progression or non-progression to diabetes.
While the plasma of individuals with recent-onset diabetes in-
duced a distinct signature relative to that of control non-diabetic
individuals and those at low or high risk of developing type 1
diabetes (i.e. autoantibody-negative siblings who either lacked
or possessed HLA-DR3 and/or -DR4 haplotypes, respectively),
the signatures of these healthy cohorts were also distinct from
one another [30]. Notably, the signature of low-risk individuals
exhibited the most robust induction of innate inflammatory
transcripts (e.g. IL-1B, chemokine [C-C motif] ligand 2
[CCL2], CCL3, CCL7, chemokine [C-X-C motif] ligand 1
[CXCL1], CXCL2, CXCL3, CD14 and triggering receptor
expressed on myeloid cells 1 [TREM1]). Pathway analyses
revealed a continuum of immune states across the four cohorts.
The plasma of individuals with recent-onset type 1 diabetes
induced signatures intermediate between those at low and high
risk of developing the disease, such that inflammation de-
creased and regulation increased across the low risk →
recent-onset disease→ high risk→ non-diabetic donor contin-
uum [30]. These results not only shed some light on the
importance of innate immunity pathways in the early stage of
the disease but they may also present new therapeutic opportu-
nities before autoantibody development.
Maximising the potential of a networked bioresource
in a complex disease setting
The studies outlined above clearly provide important break-
throughs but thus far ancillary studies have been predominant-
ly single-centre, focused on one hypothesis/question and gen-
erated from samples obtained from a few selected donors. In
the era of team science, ‘big data’ and systems biology ap-
proaches allied with high-throughput technology, TrialNet
will best move forwards by fostering models for mechanistic
studies that are bigger in scope and represent and integrate
different investigators and the myriad of data opportunities.
One approach that is gaining considerable attraction and will
become a future focus is to assemble these technologies to
address fundamentally important questions relevant to the
TrialNet mission, such as the discovery of biomarkers and
mechanisms of progression through the disease stages.
TrialNet will be able to play a major role in coordinating
external collaborations and data integration to achieve this
goal but success will also depend upon engagement with the
relevant experts. The revised model envisages mechanistic
studies that will be considered an integral, core part of
TrialNet activity and no longer ‘ancillary’.
Overall, our perspective on the achievements of the
TrialNet model of conducting wide-ranging studies ancillary
to its trials is that it has pushed the field forwards in multiple
directions, and has begun to reveal biomarkers and deliver the
mechanistic understanding required to combat this complex
and heterogeneous disease. We anticipate that the findings
expected to emerge soon from multi-dimensional analyses
addressing key transition points in the disease will build on
this platform, maximising the opportunities provided by this
precious resource.
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